Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs

Table 2 Univariate analysis of risk factor for LSR of BMD

	Lumber spine		Femoral neck
	Odds ratio	p value	Odds ratio	p value
Age (year)	0.98 (0.94–1.02)	0.28	0.98 (0.95–1.02)	0.34
Sex	0.71 (0.21–2.34)	0.57	2.25 (0.79–6.42)	0.13
Disease duration	1.03 (0.97–1.08)	0.34	0.96 (0.92–1.01)	0.10
BMI	1.04 (0.90–1.19)	0.61	0.97 (0.88–1.07)	0.53
Average dose of prednisolone	1.18 (0.99–1.41)	0.06	1.10 (0.95–1.27)	0.22
CRP	1.51 (0.99–2.30)	0.05	1.04 (0.70–1.53)	0.85
DAS28-CRP	1.33 (0.91–1.96)	0.14	1.00 (0.76–1.33)	0.99
SDAI	1.03 (0.98–1.08)	0.20	1.00 (0.97–1.04)	0.92
MHAQ	1.03 (0.95–1.11)	0.46	0.99 (0.93–1.05)	0.68
Duration of bDMARDs therapy	0.98 (0.81–1.19)	0.83	0.91 (0.79–1.05)	0.18
Type of anti-osteoporosis drugs	1.26 (0.77–2.05)	0.36	0.93 (0.66–1.32)	0.68

Univariate analysis detected no risk factors for 12-month LSR of lumbar spine (≤ − 2.4%) and femoral neck (≤ − 1.9%) BMD
LSR least significant reduction, BMD bone mineral density, BMI body mass index, CRP serum C-reactive protein concentration, DAS28-CRP Disease Activity Score-28-CRP, SDAI simplified disease activity index, MHAQ modified health assessment questionnaire, bDMARDs biologic disease-modifying anti-rheumatic drugs

ISSN: 1756-0500